Although neither correlated to clinical scales nor to disease duration atbaseline, eotaxin levels were reduced after 360 days in symptomatic carriers.Eotaxin patterns were in line with results of the microRNA study (Shi et al., 2014), and bothunbiased studies raised the hypothesis of astrocyte activation in SCA3/MJD, possiblypresent in pre-clinical phases, and evolving to exhaustion as the diseaseprogresses. Here, CCL11 is linked to Machado-Joseph disease.